Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to developing and marketing innovative treatments for mitochondrial and neuromuscular diseases. These conditions represent areas of high unmet medical need, often involving orphan and niche indications that currently lack effective therapies. The company focuses on various therapeutic segments, including neuro-ophthalmological, pulmonary, and neuromuscular diseases. Santhera primarily generates its revenue from the European Union, aiming to address significant health challenges faced by patients with these rare disorders.
Juvantia Pharma is discovers and develops pharmaceutical products for neurological and cardiovascular disorders. The company focuses on small molecule pharmaceuticals active on G-protein coupled receptors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.